<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Specialized Pro-Resolving Mediator (SPM) Therapies for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Disease</td>
<td>RvD1</td>
</tr>
<tr>
<td class="label">[Alzheimer's](/diseases/alzheimers-disease)</td>
<td>+++ Reduced plaques, improved cognition[@bisicchia2021]</td>
</tr>
<tr>
<td class="label">[Parkinson's](/diseases/parkinsons-disease)</td>
<td>+++ Protected DA neurons, reduced alpha-syn[@xu2023]</td>
</tr>
<tr>
<td class="label">[ALS](/diseases/als-amyotrophic-lateral-sclerosis)</td>
<td>++ Slowed progression, extended survival[@rekavetz2022]</td>
</tr>
<tr>
<td class="label">[CBS/PSP](/diseases/cortico-basal-syndrome)</td>
<td>+ Theoretical benefit via anti-inflammatory</td>
</tr>
<tr>
<td class="label">[FTD](/diseases/frontotemporal-dementia)</td>
<td>+ Potential neuroprotection</td>
</tr>
<tr>
<td class="label">[Huntington's](/diseases/huntingtons-disease)</td>
<td>+ Anti-inflammatory benefit</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Family</td>
</tr>
<tr>
<td class="label">RvD1 native</td>
<td>Resolvin D</td>
</tr>
<tr>
<td class="label">17R-RvD1 (AT-RvD1)</td>
<td>Resolvin D</td>
</tr>
<tr>
<td class="label">RvD2 analogs</td>
<td>Resolvin D</td>
</tr>
<tr>
<td class="label">RvE1 native</td>
<td>Resolvin E</td>
</tr>
<tr>
<td class=
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Specialized Pro-Resolving Mediator (SPM) Therapies for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Disease</td>
<td>RvD1</td>
</tr>
<tr>
<td class="label">[Alzheimer's](/diseases/alzheimers-disease)</td>
<td>+++ Reduced plaques, improved cognition[@bisicchia2021]</td>
</tr>
<tr>
<td class="label">[Parkinson's](/diseases/parkinsons-disease)</td>
<td>+++ Protected DA neurons, reduced alpha-syn[@xu2023]</td>
</tr>
<tr>
<td class="label">[ALS](/diseases/als-amyotrophic-lateral-sclerosis)</td>
<td>++ Slowed progression, extended survival[@rekavetz2022]</td>
</tr>
<tr>
<td class="label">[CBS/PSP](/diseases/cortico-basal-syndrome)</td>
<td>+ Theoretical benefit via anti-inflammatory</td>
</tr>
<tr>
<td class="label">[FTD](/diseases/frontotemporal-dementia)</td>
<td>+ Potential neuroprotection</td>
</tr>
<tr>
<td class="label">[Huntington's](/diseases/huntingtons-disease)</td>
<td>+ Anti-inflammatory benefit</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Family</td>
</tr>
<tr>
<td class="label">RvD1 native</td>
<td>Resolvin D</td>
</tr>
<tr>
<td class="label">17R-RvD1 (AT-RvD1)</td>
<td>Resolvin D</td>
</tr>
<tr>
<td class="label">RvD2 analogs</td>
<td>Resolvin D</td>
</tr>
<tr>
<td class="label">RvE1 native</td>
<td>Resolvin E</td>
</tr>
<tr>
<td class="label">RvE1 analog (RX-10045)</td>
<td>Resolvin E</td>
</tr>
<tr>
<td class="label">LxA4 analogs</td>
<td>Lipoxin</td>
</tr>
<tr>
<td class="label">PD1/NPD1 native</td>
<td>Protectin</td>
</tr>
<tr>
<td class="label">PDX</td>
<td>Protectin</td>
</tr>
<tr>
<td class="label">MaR1</td>
<td>Maresin</td>
</tr>
</table>
Specialized pro-resolving mediators (SPMs) are a family of endogenous lipid-derived autacoids that play a fundamentally distinct role from classical anti-inflammatory agents. Unlike NSAIDs or corticosteroids that broadly suppress the inflammatory cascade, SPMs actively drive the resolution of inflammation — the natural biological process by which acute inflammation terminates and tissue homeostasis is restored[@serhan2014; @buckley2014]. This distinction is critical for neurodegeneration: chronic neuroinflammation persists in diseases like [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease), in part because the resolution phase fails, leaving microglia trapped in a pro-inflammatory state.
SPMs are synthesized from omega-3 polyunsaturated fatty acids (EPA and DHA) via enzymatic oxygenation by lipoxygenases (LOX), cyclooxygenase-2 (COX-2), and cytochrome P450 enzymes[@serhan2014]. The four major families — resolvins, lipoxins, protectins, and maresins — each carry distinct receptor profiles and tissue-specific functions. In the CNS, SPMs act primarily through G-protein-coupled receptors (GPCRs) including ALX/FPR2, GPR32, ERV1/ChemR23, and BLT1 to orchestrate the transition from inflammation to homeostasis.
Classical anti-inflammatory drugs block prostaglandin or leukotriene synthesis but do not engage the resolution machinery. This can paradoxically delay healing and prolong disease states. SPMs work through a fundamentally different mechanism: they activate macrophages and microglia to perform efferocytosis (phagocytic clearance of dead cells and debris), reduce pro-inflammatory cytokine secretion, promote tissue repair, and dampen neutrophil infiltration[@serhan2014].
SPMs derive from essential fatty acid precursors through distinct enzymatic routes:
RvD1 is the prototypical D-series resolvin, produced via 17S-LOX from [DHA](/mechanisms/lipid-metabolism-dysfunction-comparison). It acts through two receptors: ALX/FPR2 (high affinity) and GPR32 (decoy/non-signaling in many species). In the CNS, RvD1 has demonstrated neuroprotective effects across multiple models.
Alzheimer's Disease: In APP/PS1 transgenic mice, RvD1 administration reduced amyloid-beta plaque burden, attenuated microglial activation (Iba-1+ cells), and improved spatial memory performance in Morris water maze tests[@bisicchia2021]. RvD1 promoted microglial phagocytosis of fluorescently labeled amyloid-beta42 oligomers in primary cell culture. The mechanism involves ALX/FPR2 receptor engagement on microglia, which activates the AMPK-SIRT1 pathway and shifts mitochondrial metabolism toward oxidative phosphorylation — a signature of M2 polarization.
Parkinson's Disease: In MPTP-induced PD models, RvD1 reduced dopaminergic neuron loss in the [substantia nigra](/brain-regions/substantia-nigra) and improved behavioral outcomes[@xu2023]. RvD1 suppressed NLRP3 inflammasome activation in microglia, reducing active caspase-1 and IL-1beta release. It also attenuated alpha-synuclein aggregation and protected mitochondrial complex I activity.
ALS: RvD1 reduced microglial neurotoxicity in SOD1G93A mouse models, slowing disease progression and extending survival by approximately 10%[@rekavetz2022].
Receptor Signaling: RvD1 binding to ALX/FPR2 triggers Gi-mediated signal transduction, decreasing cAMP and activating MAPK pathways that suppress NF-kappaB nuclear translocation.
RvD2 acts primarily through GPR18 (ERV1/ChemR23) with higher potency than RvD1 in some models[@wang2022]. It is particularly effective at reducing neutrophil infiltration and promoting efferocytosis.
Mechanisms: RvD2 reduced microglial production of ROS and nitrogen species, decreased TNF-alpha and IL-6 secretion, and enhanced phagocytosis of tau aggregates in primary neuronal cultures. It also promoted the release of anti-inflammatory cytokines including IL-10 and TGF-beta.
Therapeutic Potential: Stable RvD2 analogs (e.g., 17R-RvD2) have been developed with improved pharmacokinetics and resistance to rapid enzymatic inactivation. These analogs cross the blood-brain barrier more efficiently than native RvD2.
RvE1 is the best-characterized E-series resolvin, derived from EPA. It acts through ERV1/ChemR23 on macrophages and neutrophils and through BLT1 on neutrophils[@li2020].
Parkinson's Disease: RvE1 reduced microglial activation, protected dopaminergic neurons, and improved motor function in MPTP and 6-OHDA models. The mechanism involves inhibition of the p38 MAPK and JNK pathways in microglia, reducing production of pro-inflammatory mediators.
Alzheimer's Disease: RvE1 attenuated learning and memory deficits in 5xFAD mice by reducing amyloid-beta levels and microglial inflammation through ERV1 receptor engagement.
ALS: RvE1 administration in SOD1 mice reduced microglial activation and extended disease progression latency[@rekavetz2022].
Lipoxins (LxA4 and LxB4) are the prototypical pro-resolving mediators, generated during platelet-neutrophil interactions and neutrophil-astrocyte cross-talk.
LxA4 signals through the ALX/FPR2 receptor (shared with RvD1), making it a high-affinity ligand for this key resolution receptor[@leimeister2023; @chen2022]. Unlike resolvins, lipoxins are generated through transcellular routes, requiring cell-cell contact between different immune lineages.
Neuroprotective Mechanisms:
Alzheimer's Disease: LxA4 levels are reduced in AD patient CSF compared to age-matched controls, suggesting a deficiency in endogenous resolution mechanisms. Exogenous LxA4 administration in 3xTg-AD mice reduced amyloid-beta deposition and improved cognitive performance. The mechanism involves suppression of NLRP3 inflammasome activity in microglia.
Parkinson's Disease: LxA4 protected against 6-OHDA-induced dopaminergic toxicity by reducing microglial activation and inflammatory cytokines (TNF-alpha, IL-1beta, IL-6)[@leimeister2023].
Clinical Status: LxA4 has a short half-life (~30 minutes in plasma) due to rapid oxidation. Stable analogs (e.g., benzo-LxA4, 15-epi-LxA4) have been developed for therapeutic use. LxA4 is currently in preclinical development for neurodegenerative indications.
Aspirin acetylated COX-2 to produce 15R-HETE, which is converted to aspirin-triggered lipoxins (ATL) that retain bioactivity with enhanced stability. Low-dose aspirin may provide neuroprotective effects in part through ATL generation — an important link between a widely used medication and resolution pharmacology.
Protectins are generated from [DHA](/mechanisms/lipid-metabolism-dysfunction-comparison) via 15-LOX-1 and are particularly enriched in neural tissue. The prefix "neuro" is used when protectins are generated in nervous system tissue.
PD1 was first identified in brain tissue and has become one of the most studied SPMs in neurodegeneration[@wang2016; @bazan2013].
Alzheimer's Disease: NPD1 is dramatically reduced in AD brain tissue and CSF. In APP/PS1 and 3xTg-AD models, PD1 administration:
Parkinson's Disease: NPD1 protected against MPTP-induced dopaminergic loss and improved behavioral outcomes. The mechanism involves reduction of microglial NADPH oxidase activity and suppression of iNOS expression.
PDX is a recently characterized protectin with dual anti-inflammatory and pro-resolving properties — it inhibits leukotriene formation while simultaneously activating resolution programs[@koltsida2021].
Therapeutic Advantages: PDX has a longer half-life than NPD1 and shows potent activity at lower concentrations. In AD models, PDX attenuated neuroinflammation, improved mitochondrial function, and reduced amyloid-beta burden[@yang2023].
Maresins (MaR) are produced by macrophages via 14-LOX from DHA and are particularly involved in tissue regeneration and repair[@liu2022].
MaR1 promotes tissue repair through macrophage-mediated mechanisms:
Alzheimer's and Parkinson's: MaR1 reduced microglial inflammation and protected neurons in both AD and PD models. The mechanism involves the ALX/FPR2 receptor and activation of the TGF-beta/Smad signaling pathway.
ALS: MaR1 promoted motor neuron survival and enhanced functional recovery in SOD1 mouse models[@liu2022].
MaR2 is a more recently identified maresin with similar but distinct bioactivity from MaR1. It acts through the same LXA4/ALX and GPR32 receptors and demonstrates comparable resolution activity.
Key: +++ strong preclinical evidence, ++ moderate evidence, + theoretical/early
SPM Analogs: Chemical modification of native SPMs to improve metabolic stability and BBB penetration is the primary near-term strategy. 17R-stereoisomers (aspirin-triggered forms) are generally more stable than native 17S forms.
Aspirin at Low Dose: Daily low-dose aspirin produces endogenous AT-SPMs (AT-RvD, AT-LxA4) via COX-2 acetylation. This may contribute to aspirin's observed inverse association with AD/PD risk in epidemiological studies. However, aspirin carries bleeding risks that limit long-term use.
Omega-3 Fatty Acid Supplementation: EPA and DHA supplementation increases SPM precursor pools. High-dose [omega-3 fatty acid therapy](/therapeutics/omega-3-fatty-acid-neurodegeneration) can increase endogenous SPM production, particularly when combined with aspirin. However, conversion efficiency varies by individual and decreases with age.
Synthetic FPR2/ALX Agonists: BMS-986253 (a lipoxin mimetic) is in clinical trials for inflammatory conditions and could be repurposed for neurodegeneration. FPR2 agonists bypass the SPM biosynthesis pathway entirely.
Nanoparticle Delivery: SPMs loaded into lipid nanoparticles or exosomes can be targeted to CNS microglia with improved brain penetration. This approach is in early preclinical development.
The unifying mechanism by which all SPMs exert neuroprotective effects is the switching of microglia from a pro-inflammatory (M1) phenotype to a pro-repair (M2) phenotype. This is not a binary switch but a spectrum, and SPMs push the equilibrium toward the repair-promoting state.
Neurodegeneration involves profound [lipid metabolism dysfunction](/mechanisms/lipid-metabolism-dysfunction-comparison) — omega-3 PUFA levels are reduced in AD and PD brains, SPM precursor availability is decreased, and the balance between pro-inflammatory eicosanoids and pro-resolving SPMs is disrupted. This is not merely a consequence of disease but an active driver of pathology.
The [APOE epsilon-4 allele](/genes/apoe) — the strongest genetic risk factor for [late-onset Alzheimer's](/diseases/alzheimers-disease) — is associated with impaired lipid transport and reduced omega-3 incorporation into neuronal membranes, potentially contributing to SPM deficiency. Conversely, [omega-3 supplementation](/therapeutics/omega-3-fatty-acid-neurodegeneration) and [ketogenic diets](/therapeutics/ketogenic-diet-neurodegeneration) that increase PUFA availability may support endogenous SPM synthesis.
SPM-based therapies represent a fundamentally novel approach to neurodegenerative disease treatment — one that addresses the root cause of persistent neuroinflammation rather than simply suppressing symptoms. They fit into the emerging "resolution pharmacology" paradigm that is particularly relevant for diseases where inflammation has become self-sustaining.
SPMs should be considered alongside:
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
Related Analyses: